Evidence map›Paper›PMID 33561626›Full record

ArticleBiomaterials2021

Point-source burst of coordination polymer nanoparticles for tri-modality cancer therapy.

Xiang Ling, Wenbo Han, Xiaomin Jiang, Xing Chen, Megan Rodriguez, Pingping Zhu, Tong Wu, Wenbin Lin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Platinum-based combination nanomedicines for cancer therapy.Current opinion in chemical biology · 2023
    Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Xiang LingDepartment of Chemistry, The University of Chicago, Chicago, IL, 60637, United States.
Wenbo HanDepartment of Chemistry, The University of Chicago, Chicago, IL, 60637, United States.
Xiaomin JiangDepartment of Chemistry, The University of Chicago, Chicago, IL, 60637, United States.
Xing ChenDepartment of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, China.
Megan RodriguezDepartment of Chemistry, The University of Chicago, Chicago, IL, 60637, United States.
Pingping ZhuDepartment of Chemistry, The University of Chicago, Chicago, IL, 60637, United States.
Tong WuDepartment of Chemistry, The University of Chicago, Chicago, IL, 60637, United States.
Wenbin LinDepartment of Chemistry, The University of Chicago, Chicago, IL, 60637, United States; Department of Radiation and Cellular Oncology and Ludwig Center for Metastasis Research, The University of Chicago, Chicago, IL, 60637, United States. Electronic address: wenbinlin@uchicago.edu.
University of Chicago · USFudan University · CN

Funding

VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI CHIEN-MIN KAO · 1985 to 2026
$122.1M
Nanoscale Coordination Polymers Co-deliver Chemotherapeutics and siRNAs for Efficacious Treatment of Resistant Ovarian CancerR01CA216436 · NCI · UNIVERSITY OF CHICAGO · PI LIN, WENBIN · 2018 to 2022
$2.1M
Targeted Nanomedicines with Synergistic Chemotherapeutics to Enhance Immunotherapy of Metastatic Colorectal CancerR01CA223184 · NCI · UNIVERSITY OF CHICAGO · PI LIN, WENBIN · 2018 to 2022
$1.8M
NCI NIH HHS P30 CA014599NCI NIH HHS R01 CA216436NCI NIH HHS R01 CA223184
6 · The paper itself

Abstract

Cancer immunotherapy, particularly the inhibition of immune checkpoints with neutralizing antibodies, has revolutionized the treatment of some cancer patients. However, immune checkpoint blockade has not provided survival benefits to most patients with colorectal and ovarian cancers. This work reports the design of acid-sensitive core-shell nanoscale coordination polymer particles (NCP) comprising a carboplatin prodrug and an siRNA against PD-L1 (siPD-L1) in the core and digitoxin on the shell for tri-modality cancer therapy. Upon cellular uptake, NCP particles rapidly burst in acidic organelles to release carboplatin for apoptosis, digitoxin for inducing immunogenicity, and siPD-L1 for PD-L1 knockdown. With long blood circulation and high tumor accumulation, NCP particles efficiently suppress the growth and metastasis of syngeneic cancers through reactivating innate and adaptive immune responses. NCP particles thus provide a promising platform to synergistically combine chemotherapy and immunotherapy for the treatment of advanced and aggressive cancers.

Indexed as

NanoparticlesNeoplasmsCarboplatinHumansImmunotherapyPolymersCarboplatinPolymersImmunogenic cell deathNanoscale coordination polymerPD-L1Point-source burstTumor

Identifiers

PMID33561626
PMCPMC8020625
OpenAlexW3128758274

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.